Novartis investigative site

Springfield, Massachusetts 01107

0 studies enrolling now · 9 studies all time

What they study most

Age-Related Macular Degeneration, Alzheimer Disease, Diabetic Macular Edema, Heart Failure, Hepatitis C, Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections — Stopped early
• Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes. — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline — Completed